The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.

Cancer Med · 2022 · PMC9160807 · PMID 35182029

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Cohort C showed a trend toward a longer survival time compared to cohort B, but the difference was not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.